| Literature DB >> 31013925 |
Michael E Lindquist1, Mark D Hicar2.
Abstract
The etiology of Kawasaki disease (KD), the leading cause of acquired heart disease in children, is currently unknown. Epidemiology supports a relationship of KD to an infectious disease. Several pathological mechanisms are being considered, including a superantigen response, direct invasion by an infectious etiology or an autoimmune phenomenon. Treating affected patients with intravenous immunoglobulin is effective at reducing the rates of coronary aneurysms. However, the role of B cells and antibodies in KD pathogenesis remains unclear. Murine models are not clear on the role for B cells and antibodies in pathogenesis. Studies on rare aneurysm specimens reveal plasma cell infiltrates. Antibodies generated from these aneurysmal plasma cell infiltrates showed cross-reaction to intracellular inclusions in the bronchial epithelium of a number of pathologic specimens from children with KD. These antibodies have not defined an etiology. Notably, a number of autoantibody responses have been reported in children with KD. Recent studies show acute B cell responses are similar in children with KD compared to children with infections, lending further support of an infectious disease cause of KD. Here, we will review and discuss the inconsistencies in the literature in relation to B cell responses, specific antibodies, and a potential role for humoral immunity in KD pathogenesis or diagnosis.Entities:
Keywords: B cells; aggresomes; antibodies; endothelial; inclusions; plasmablasts; virus-like particles
Mesh:
Substances:
Year: 2019 PMID: 31013925 PMCID: PMC6514959 DOI: 10.3390/ijms20081834
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Advanced clinical trials for treatments to prevent coronary aneurysms in Kawasaki Disease.
| Drug | Clinical Trials | Phase | Status | Closure Date | Results Summary or Comments |
|---|---|---|---|---|---|
| Infliximab | NCT02298062 | 3 | completed | September, 2015 | |
| Infliximab | NCT00760435 | 3 | resulted | October, 2012 | Improved defervescence, well tolerated, variable z- score reduction [ |
| Infliximab | NCT01596335 | 3 | resulted | October, 2014 | Improved defervescence, well tolerated [ |
| Infliximab | NCT03065244 | 3 | recruiting | September, 2020 | |
| Etanercept | NCT00841789 | 2 | Active, not recruiting | August, 2018 | |
| Anakinra | NCT02179853 | 2 | recruiting | December, 2020 | |
| Anakinra | NCT02390596 | 2 | Recruiting | April, 2019 | |
| IVIG doses | NCT00000520 | 3 | Completed | November, 1989 | Single dose of IVIG is better than splitting doses [ |
| IVIG + pulsed steroids | NCT00132080 | 3 | Completed | March, 2005 | No difference, refractory lower number than expected [ |
| IVIG 1 g or 2 g | NCT02439996 | 3 | Completed | September, 2016 | |
| IVIG + 5 days prednisolone | NCT03200561 | 3 | Recruiting | December, 2020 | Proposal published [ |
| IVIG without Aspirin | NCT02951234 | na | Recruiting | August, 2019 | Proposal published [ |
Na- not applicable; z- score- standard deviations from the mean.
Putative anti-Kawasaki disease etiology antibodies.
| Monoclonal Antibody Clones | Clonal Members | Exact Replicants | IG Isotypes | VH ^ CDR3 Length | Nucleotide Substitutions (%) | VH R/S * CDR1 | VH R/S * CDR2 | VL & CDR3 length | Nucleotide substitutions (%) | VL R/S * CDR1 | VL R/S * CDR2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-01 | 10 | 5 | G1 | 19 | 97.8 | 0 | 1/0 | 11 | 97.7 | 7 | 0 |
| 24-02 | 4 | 4 | M; G1 | 19 | 93.8 | 2/0 | 5 | 9 | 95.0 | 3/0 | 0 |
| 24-25 | 6 | 2 | G1,3 | 17 | 94.4 | 5/0 | 3/0 | 9 | 95.3 | 2/0 | 2/0 |
| 24-29 | 6 | 2 | G1,2,3 | 11 | 85.6 | 4.5 | 14/0 | 8 | 85.8 | 5 | 4 |
| 24-39 | 5 | 2 | G1 | 15 | 90.6 | 2.3 | 2.1 | 11 | 94.6 | 2 | 8/0 |
| 24-49 | 3 | 2 | G2 | 20 | 93.4 | 1.5 | 5 | 13 | 96.5 | 0 | 2/0 |
| 24-67 | 5 | G1 | 18 | 93.5 | 4.3 | 19.5 | 9 | 97.0 | 9/0 | 5 | |
| 24-377 | 4 | G1 | 14 | 92.3 | 8.0 | 6.0 | 9 | 96.2 | 9.0 | 0.5 | |
| 24-439 | 2 | M; G2 | 11 | 91.5 | 4.0 | 2.0 | 11 | 94.4 | 2/0 | 2/ | |
| 24-441/659 | 15 | M; G1 | 11 | 93.1 | 31.0 | 30.0 | 9 | 97.6 | 6.5 | 18/0 | |
| 24-595 | 5 | M; G1,2 | 15 | 93.0 | 9.5 | 13/0 | 9 | 95.6 | 2.7 | 0 | |
| 24-815 | 8 | M; G1 | 15 | 95.4 | 5.5 | 9.0 | 10 | 97.7 | 4 | 9/0 | |
| 24-893 | 4 | G1 | 12 | 91.7 | 2.3 | 2.4 | 10 | 94.4 | 19/0 | 8 | |
| 24-908 | 3 | M; G1,3 | 20 | 96.5 | 4.0 | 2.5 | 9 | 98 | 5 | 2 |
^ VH- heavy chain variable region, & VL light chain variable region, * Replacement to silent nucleotide mutation ratios (R/S).
Possible ways humoral immunity plays a role in KD.
| Possible Importance | Contrary Findings and Considerations | |
|---|---|---|
| Efficacy of IVIG | Theoretically can provide antibodies to specific etiology | Function in KD theoretical, many different potential functions of IVIG |
| Treatment with anti-CD20 antibody | Directly downregulates IG production | Limited reports and no prospective trials |
| Response to IL-1 inhibitors | Downregulates IG production, mouse models support IL-1 role | Many other broad affects |
| Coronary plasma cell infiltrates | Seen on coronary path specimens, theorized direct response to infectious agent | Plasma cell infiltrates also seen in autoimmune disorders |
| Anti-self antibodies | Can cause apoptosis of endothelial cells | Later finding, not universally seen; unclear if part of etiology or response to tissue damage |
| Plasmablast (PB) level | Level similar to infection, may be set off by etiology of KD | Number of coinfections and IVIG may make defining specificity difficult |
| PB timing | Similar to that of infection | Pure autoimmune has PB rise, but often higher/flare correlated |